1 August 2026 | ASX: MSB; Nasdaq: MESO Financial Results & Operational Update for period ended June 30, 2026 1 2 This presentation includes forward-looking statements an d fo recasts that relate to future events or our future financial performance and involve known and unknown risks,...
Annual Financial Results Presentation
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Mesoblast
- Preliminary Final Report including Appendix 4E
- Appendix 3Y - Philip Krause
- Notification regarding unquoted securities - MSB
- Mesoblast 2026 Full Year Financial Results Webcast
- Major Milestone Treatment Completed in P3 Trial for CLBP
Later from Mesoblast
- MSB Annual Financial Results and Operational Update
- Mesoblast Reports Substantial Revenue Growth to US$120M
- Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)
- Ceasing to be a substantial holder
- FDA Approves New Potency Assay for Commercial Ryoncil
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast